Lorlatinib shows therapeutic potential in advanced ROS1-positive NSCLC
The third-generation tyrosine kinase inhibitor lorlatinib appears to be safe and have potent therapeutic effect in advanced nonsmall-cell lung cancer (NSCLC) harbouring ROS1 mutation, including patients with central nervous system metastases and those with previous crizotinib exposure, according to the results of a phase I/II trial.